Latest Breaking News On - B cell depletion - Page 1 : comparemela.com

Obinutuzumab Use Decreases Incidence of Steroid-Requiring cGVHD After Transplant

Utilizing obinutuzumab to enhance B-cell depletion significantly reduced the need for corticosteroids and increased relapse-free survival in patients with steroid-requiring chronic graft-vs-host disease undergoing well-matched hematopoietic stem cell transplant.

Dana farber cancer instituteUnited statesCorey cutlerStanford universityNational institute of healthFritz laboratoryNational instituteB cell depletionChronic graft vs host diseaseHematopoietic stem cell transplantPhase 2 study nct028673842023 ash annual meeting

Rituximab not noninferior to ocrelizumab for relapsing-remitting multiple sclerosis

Rituximab not noninferior to ocrelizumab for relapsing-remitting multiple sclerosis
medicalxpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medicalxpress.com Daily Mail and Mail on Sunday newspapers.

Lauren oommenIzanne roosRoyal melbourne hospitalRelapsing remitting multiple sclerosisNew approachesChallenge old assumptionsB cell depletionMultiple sclerosis

Horizon Therapeutics (HZNP) Reports New Strong Data of UPLIZNA Phase 3 Trial Data

Horizon Therapeutics (HZNP) Reports New Strong Data of UPLIZNA Phase 3 Trial Data
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesNoord hollandKristina pattersonNeuromyelitis opticaBruce creeNeuroimmunol neuroinflammAyala mdelTina venturaGarrido edeRachel vannProduct communicationsDj associationEuropean commissionDrug administrationExchange commissionResearch in multiple sclerosis

Horizon Therapeutics plc: New Analysis of UPLIZNA (inebilizumab-cdon) Phase 3 Trial Data Demonstrates Importance of Reducing Plasmablasts to Help Prevent Neuromyelitis Optica Spectrum Disorder (NMOSD) Attacks

Separate analysis also being presented at ECTRIMS 2022 reinforces the efficacy of UPLIZNA in patients with genetic variations Horizon Therapeutics plc (Nasdaq: HZNP) today announced new data

United statesNoord hollandKristina pattersonNeuromyelitis opticaBruce creeRay gordonNeuroimmunol neuroinflammAyala mdelTina venturaGarrido edeRachel vannProduct communicationsDj associationEuropean commissionDrug administrationExchange commission

TG Therapeutics Announces Presentation of Exploratory

NEW YORK, Oct. 26, 2022 (GLOBE NEWSWIRE) TG Therapeutics, Inc. (NASDAQ: TGTX), today announced presentations highlighting exploratory analyses from.

United statesStanford universityUniversity of california san franciscoRound rockSan franciscoEnrique alvarezLawrence steinmanEdwardj foxMichaels weissSibyl wrayBruceac creeZimmermann professor of neurology neurological sciencesMd stanford universityDrug administrationGlobe newswire tg therapeutics incUniversity of colorado